28329872|t|Doxorubicin Has Dose-Dependent Toxicity on Mouse Ovarian Follicle Development, Hormone Secretion, and Oocyte Maturation
28329872|a|Doxorubicin (DOX), one of the most commonly used anticancer medications, has been reported to affect fertility by damaging ovarian follicles; however, the dose-dependent toxicity of DOX on the dynamic follicle development and oocyte maturation has not been well-defined. Our objective is to determine the effects of human - relevant exposure levels of DOX on follicular functions across developmental time. In vitro cultured multilayered secondary mouse follicles were treated with DOX at 0, 2, 20, 100, and 200 nM for 24 h, and follicle development, hormone secretion, and oocyte maturation were analyzed. DOX caused dose-dependent toxicity on follicle growth, survival, and secretion of 17β-estradiol (E2). At 200 nM, DOX induced DNA damage and apoptosis in follicle somatic cells first and then in oocytes, which was correlated with the uptake of DOX first to the somatic cells followed by germ cells. Follicles treated with DOX at 0, 2, and 20 nM showed similar oocyte metaphase II (MII) percentages after in vitro oocyte maturation; however, 20 nM DOX significantly increased the number of MII oocytes with abnormal spindle morphology and chromosome misalignment. In an effort to harmonize the in vitro study to in vivo treatment, dose-dependent toxicity on oocyte meiotic maturation was found in 16-day-old CD-1 mice treated with DOX at 0, 0.4, 2, and 10 mg/kg, consistent with the in vitro oocyte maturation outcomes. Our study demonstrates that DOX has dose-dependent toxicity on ovarian follicle development, hormone secretion, and oocyte maturation, which are three key factors to support the female reproductive and endocrine functions.
28329872	0	11	Doxorubicin	T109,T195	C0013089
28329872	16	30	Dose-Dependent	T081	C1512045
28329872	31	39	Toxicity	T037	C0600688
28329872	43	48	Mouse	T015	C0025929
28329872	49	65	Ovarian Follicle	T023	C0018120
28329872	66	77	Development	T039	C0243107
28329872	79	96	Hormone Secretion	T042	C0312431
28329872	102	119	Oocyte Maturation	T043	C1160520
28329872	120	131	Doxorubicin	T109,T195	C0013089
28329872	133	136	DOX	T109,T195	C0013089
28329872	155	163	commonly	T081	C0205214
28329872	169	191	anticancer medications	T109,T121	C0003392
28329872	221	230	fertility	T040	C0015895
28329872	234	242	damaging	T169	C1883709
28329872	243	260	ovarian follicles	T023	C0018120
28329872	275	289	dose-dependent	T081	C1512045
28329872	290	298	toxicity	T037	C0600688
28329872	302	305	DOX	T109,T195	C0013089
28329872	313	320	dynamic	T169	C0729333
28329872	321	329	follicle	T023	C0018120
28329872	330	341	development	T039	C0243107
28329872	346	363	oocyte maturation	T043	C1160520
28329872	395	404	objective	T170	C0018017
28329872	425	435	effects of	T080	C1704420
28329872	436	441	human	T016	C0086418
28329872	444	452	relevant	T080	C2347946
28329872	453	461	exposure	T080	C0332157
28329872	462	468	levels	T080	C0441889
28329872	472	475	DOX	T109,T195	C0013089
28329872	479	489	follicular	T023	C0018120
28329872	490	499	functions	T169	C0542341
28329872	507	520	developmental	T039	C0243107
28329872	521	525	time	T079	C0040223
28329872	527	535	In vitro	T080	C1533691
28329872	536	544	cultured	T059	C0430400
28329872	545	583	multilayered secondary mouse follicles	T023	C0737234
28329872	589	596	treated	T169	C1522326
28329872	602	605	DOX	T109,T195	C0013089
28329872	649	657	follicle	T023	C0018120
28329872	658	669	development	T039	C0243107
28329872	671	688	hormone secretion	T042	C0312431
28329872	694	711	oocyte maturation	T043	C1160520
28329872	727	730	DOX	T109,T195	C0013089
28329872	738	752	dose-dependent	T081	C1512045
28329872	753	761	toxicity	T037	C0600688
28329872	765	780	follicle growth	T042	C1155902
28329872	782	790	survival	T169	C0220921
28329872	796	805	secretion	T042	C0312431
28329872	809	822	17β-estradiol	T109,T121,T125	C0014912
28329872	824	826	E2	T109,T121,T125	C0014912
28329872	840	843	DOX	T109,T195	C0013089
28329872	844	851	induced	T169	C0205263
28329872	852	862	DNA damage	T049	C0012860
28329872	867	876	apoptosis	T043	C0162638
28329872	880	888	follicle	T023	C0018120
28329872	889	902	somatic cells	T025	C1257909
28329872	921	928	oocytes	T025	C0029045
28329872	960	966	uptake	T039	C0243144
28329872	970	973	DOX	T109,T195	C0013089
28329872	987	1000	somatic cells	T025	C1257909
28329872	1013	1023	germ cells	T025	C0017471
28329872	1025	1034	Follicles	T023	C0018120
28329872	1035	1042	treated	T169	C1522326
28329872	1048	1051	DOX	T109,T195	C0013089
28329872	1086	1092	oocyte	T025	C0029045
28329872	1093	1105	metaphase II	T043	C1155832
28329872	1107	1110	MII	T043	C1155832
28329872	1112	1123	percentages	T081	C0439165
28329872	1130	1138	in vitro	T080	C1533691
28329872	1139	1156	oocyte maturation	T043	C1160520
28329872	1173	1176	DOX	T109,T195	C0013089
28329872	1191	1200	increased	T081	C0205217
28329872	1215	1218	MII	T043	C1155832
28329872	1219	1226	oocytes	T025	C0029045
28329872	1232	1240	abnormal	T033	C0205161
28329872	1241	1248	spindle	T026	C1166795
28329872	1249	1259	morphology	T080	C0332437
28329872	1264	1274	chromosome	T026	C0008633
28329872	1275	1287	misalignment	T080	C1275957
28329872	1319	1333	in vitro study	T062	C0681828
28329872	1337	1344	in vivo	T082	C1515655
28329872	1345	1354	treatment	T169	C1522326
28329872	1356	1370	dose-dependent	T081	C1512045
28329872	1371	1379	toxicity	T037	C0600688
28329872	1383	1408	oocyte meiotic maturation	T043	C1160520
28329872	1433	1442	CD-1 mice	T015	C0025929
28329872	1443	1450	treated	T169	C1522326
28329872	1456	1459	DOX	T109,T195	C0013089
28329872	1488	1503	consistent with	T078	C0332290
28329872	1508	1516	in vitro	T080	C1533691
28329872	1517	1534	oocyte maturation	T043	C1160520
28329872	1535	1543	outcomes	T169	C1274040
28329872	1549	1554	study	T062	C2603343
28329872	1573	1576	DOX	T109,T195	C0013089
28329872	1581	1595	dose-dependent	T081	C1512045
28329872	1596	1604	toxicity	T037	C0600688
28329872	1608	1624	ovarian follicle	T023	C0018120
28329872	1625	1636	development	T039	C0243107
28329872	1638	1655	hormone secretion	T042	C0312431
28329872	1661	1678	oocyte maturation	T043	C1160520
28329872	1700	1707	factors	T169	C1521761
28329872	1723	1742	female reproductive	T040	C0278049
28329872	1747	1766	endocrine functions	T039	C0678896